Eledon Pharmaceuticals, Inc.

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for life-threatening conditions. The company's mission is centered on "One Transplant For Life," aiming to significantly improve the longevity of transplanted organs and enhance the overall health and quality of life for transplant recipients. Headquartered in Irvine, California, Eledon Pharmaceuticals leverages its immunology expertise to address critical unmet medical needs.

The company's lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody designed to target the CD40 Ligand pathway. This pathway plays a central role in immune responses, making it a validated biological target with broad therapeutic potential. Eledon is conducting preclinical and clinical studies for tegoprubart across various market segments, including kidney, liver, and islet cell allotransplantation, xenotransplantation, and the treatment of amyotrophic lateral sclerosis (ALS).

Recent notable developments include the U.S. Food and Drug Administration (FDA) granting Orphan Drug designation to tegoprubart for the prevention of allograft rejection in liver transplantation in March 2026. The company also reported its fourth quarter and full-year 2025 operating and financial results in March 2026. In January 2026, Eledon highlighted favorable efficacy, safety, and tolerability data from its Phase 2 BESTOW trial for kidney transplantation, supporting advancement into Phase 3 development. Additionally, tegoprubart has shown positive preliminary results in investigator-initiated islet transplant trials for Type 1 Diabetes, with some patients achieving insulin independence for over a year, and has been utilized in xenotransplantation procedures, including pig-to-human kidney transplants. David-Alexandre C. Gros, M.D., serves as the Chief Executive Officer, leading the company's strategic direction.